Gynecare to submit ThermaChoice premarket approval (PMA) in June
This article was originally published in Clinica
Executive Summary
Gynecare is to submit trial results of its ThermaChoice menorrhagia device in support of a PMA application this June. The device is an investigational, eight-minute treatment for excessive menstrual bleeding and is intended to be performed under local anaesthetic.